David Gould, MD
Child & Adolescent Psychiatry · Richmond, VANPI 1629068077
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 496 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 34 manufacturers, the largest accounting for just 10.0% — the pattern of someone who eats at a lot of different presentations. Among child & adolescent psychiatry clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 496 payments — averaging $18.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Supernus Pharmaceuticals, Inc.$900
- Otsuka America Pharmaceutical, Inc.$734
- Corium, LLC$710
- Sunovion Pharmaceuticals Inc.$617
- Johnson & Johnson$611
- Ironshore Pharmaceuticals Inc.$538
- plus $5K from 28 others
What the payments were for
- Food & beverage$8,966100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Supernus Pharmaceuticals, Inc. | 37 | $900 |
| Otsuka America Pharmaceutical, Inc. | 38 | $734 |
| Corium, LLC | 31 | $710 |
| Sunovion Pharmaceuticals Inc. | 48 | $617 |
| Johnson & Johnson | 27 | $611 |
| Ironshore Pharmaceuticals Inc. | 31 | $538 |
| Takeda Pharmaceuticals U.S.A., Inc. | 33 | $537 |
| Vanda Pharmaceuticals Inc. | 26 | $518 |
| Neurocrine Biosciences, Inc. | 23 | $458 |
| Tris Pharma Inc | 30 | $442 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 24 | $395 |
| Alkermes, Inc. | 15 | $327 |
| Lundbeck LLC | 17 | $315 |
| Axsome Therapeutics, Inc. | 12 | $301 |
| AbbVie | 29 | $271 |
| E.r. Squibb & Sons, L.L.C. | 11 | $212 |
| Almatica Pharma LLC | 7 | $135 |
| Teva Pharmaceuticals USA, Inc. | 8 | $129 |
| Neos Therapeutics, LP | 7 | $108 |
| Neuronetics, Inc. | 4 | $107 |
| Eisai Inc. | 5 | $83 |
| Shire North American Group Inc | 6 | $79 |
| Noven Therapeutics, LLC | 5 | $66 |
| Collegium Pharmaceutical, Inc. | 3 | $57 |
| Bausch Health US, LLC | 3 | $57 |
| Vertical Pharmaceuticals, LLC | 3 | $52 |
| Merck | 4 | $52 |
| TMS Neurohealth Centers Inc. | 2 | $37 |
| Alfasigma USA, Inc. | 2 | $35 |
| Harmony Biosciences LLC | 1 | $24 |
| Amgen | 1 | $17 |
| Jazz Pharmaceuticals Inc. | 1 | $15 |
| Arbor Pharmaceuticals, Inc. | 1 | $13 |
| Idorsia Pharmaceuticals US Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- QELBREE$382
How this compares
$8,966 in reported general payments places this provider in the 95th percentile of 115 child & adolescent psychiatry providers in Virginia.
See all child & adolescent psychiatry providers in Virginia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrintellixVortioxetine Hydrobromide | 35 | $16,870 |
| FetzimaLevomilnacipran Hcl | 24 | $11,831 |
| Focalin XrDexmethylphenidate Hcl | 12 | $3,052 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 42 | $3,049 |
| Dexmethylphenidate Hcl ErDexmethylphenidate Hcl | 13 | $2,533 |
| Aripiprazole | 28 | $2,076 |
| Olanzapine | 44 | $1,160 |
| Duloxetine Hcl | 82 | $1,147 |
| Quetiapine Fumarate | 50 | $642 |
| Sertraline Hcl | 69 | $624 |
| Atomoxetine Hcl | 12 | $597 |
| Trazodone Hcl | 69 | $587 |
| Risperidone | 46 | $538 |
| Guanfacine Hcl ErGuanfacine Hcl | 28 | $503 |
| Oxcarbazepine | 19 | $483 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $537 | $16,87035 claims |
| AbbVieFetzima | $271 | $11,83124 claims |
| Almatica Pharma LLCSertraline Hcl | $135 | $62469 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 115 child & adolescent psychiatry providers in Virginia.
Other child & adolescent psychiatry in Richmond
- Charles HallRichmond$10K
- Craig SwaineyRichmond$5K
- Jhansi MeadRichmond$2K
- Rajinderpal SinghRichmond$2K
- Rosa Morales-TheodoreRichmond$1K
- Hadley McPhersonRichmond$475
- Chandramouleswar AmaraPetersburg$10K
- Rakesh ShahHopewell$7K
- Vikas MangewalaFairfax$7K
- Maria Carmen Rita Gonzales VigilarAshburn$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.